Related Experiment Videos
Effects of the convulsant methionine sulfoximine on striatal dopamine metabolism
Abstract:
Experiments were conducted to investigate the effects of the convulsant L-methionine-DL-sulfoximine (MSO) on striatal dopamine (DA) metabolism. Intraventricular injections of MSO produced a transient increase in striatal DA release followed by inhibition of DA release for up to 3 days, which paralleled the inhibition by MSO of the enzyme glutamine synthetase (GS). DA synthesis was decreased for up to 24 h after injection of MSO, but returned to normal within 3 days after MSO administration. Intrastriatal injections of MSO produced a pronounced decrease in striatal DA release and inhibition of striatal GS activity 24 h postinjection but, unlike intraventricular MSO, did not produce behavioral convulsions. Glutamate-DA interactions may be responsible for the observed effects.
Insights
L-methionine-DL-sulfoximine (MSO) disrupts striatal dopamine (DA) metabolism by inhibiting glutamine synthetase (GS). This leads to altered DA release and synthesis, with potential glutamate-DA interactions underlying these effects.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Striatal dopamine (DA) plays a crucial role in motor control and reward.
- Glutamine synthetase (GS) is a key enzyme in neurotransmitter metabolism.
- L-methionine-DL-sulfoximine (MSO) is a known convulsant that inhibits GS.
Purpose of the Study:
- To investigate the effects of MSO on striatal dopamine metabolism.
- To explore the relationship between GS inhibition and DA release/synthesis.
- To examine the role of glutamate-DA interactions in MSO-induced neurochemical changes.
Main Methods:
- Intraventricular and intrastriatal injections of MSO in experimental models.
- Measurement of striatal dopamine release and synthesis.
- Assay of glutamine synthetase (GS) activity.
- Observation of behavioral effects.
Main Results:
- Intraventricular MSO transiently increased then inhibited striatal DA release for up to 3 days, paralleling GS inhibition.
- DA synthesis was decreased for 24 hours post-MSO injection.
- Intrastriatal MSO decreased DA release and GS activity but did not induce convulsions.
- MSO-induced changes in DA metabolism were linked to GS inhibition.
Conclusions:
- MSO significantly alters striatal dopamine metabolism through glutamine synthetase inhibition.
- The route of MSO administration influences its effects on DA release and behavioral outcomes.
- Glutamate-dopamine interactions are implicated in the neurochemical effects of MSO.